Robert Orlowski, Deputy Chair of Lymphoma/Myeloma, Vice Chair of MM Research, and Florence Maude Thomas Cancer Research Professor at the University of Texas MD Anderson Cancer Center, shared a post on X:
“Myeloma Paper of the Day: German analysis of 343 triple-class exposed relapsed/refractory patients who received ide-cel or cilta-cel finds cilta with higher CR rate (61% vs. 39%) and improved response conversion with more CRs after starting from <CR pre-CAR.”
Title: Remission conversion drives outcomes after CAR T-cell therapy for multiple myeloma: a registry analysis from the DRST
Authors: Maximilian Merz, Nico Gagelmann, Samih Smaili, Sarah Flossdorf, Sandra Sauer, Christof Scheid, Bastian von Tresckow, Gerald Georg Wulf, Katja C Weisel, Igor Blau, Monika Engelhardt, Ralph Wäsch, Natalie Schub, Raphael Teipel, Judith S. Hecker, Johannes M. Waldschmidt, Britta Besemer, Ben-Niklas Baermann, Simon Call, Leo Hansmann, Francis Ayuketang Ayuk, Marc S. Raab, Hermann Einsele, Uwe Platzbecker, Nicolaus Kröger
You can read the Full Article in Blood.
More posts featuring Robert Orlowski.
